Omeros (OMER) Return on Capital Employed (2011 - 2026)
Omeros' (OMER) quarterly Return on Capital Employed came in at 42.7% in Q1 2026, up 5151.0% year-on-year from 0.81% in Q1 2025, and up 38.23% quarter-over-quarter from 69.14% in Q4 2025.
Omeros (OMER) Return on Capital Employed (2011 - 2026) Analysis & Trends
Omeros has disclosed Return on Capital Employed across 16 years of filings, most recently posting 42.7% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 42.7%, up 5151.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 42.7% (up 5151.0% YoY), and the FY2025 annual result was 54.99%, up 1229.0% from the prior year.
- Return on Capital Employed came in at 42.7% for Q1 2026 at Omeros, up from 69.14% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.6% in Q1 2023 to a low of 113.07% in Q3 2025.
- The 5-year median for Return on Capital Employed is 48.12% (2024), against an average of 59.69%.
- Across the five-year window, Return on Capital Employed surged 13376 bps in 2022 and plunged 5098 bps in 2025, its largest moves.
- Omeros' Return on Capital Employed stood at 42.12% in 2022, then dropped by 2 bps to 43.03% in 2023, then slumped by 80 bps to 77.41% in 2024, then increased by 11 bps to 69.14% in 2025, then surged by 38 bps to 42.7% in 2026.
- The last three Return on Capital Employed figures came in at 42.7% (Q1 2026), 69.14% (Q4 2025), and 113.07% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Omeros | 628.56 Mn | 493.24 Mn | 9.31 Mn | -42.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.70% |
| Dec 31, 2025 | -69.14% |
| Sep 30, 2025 | -113.07% |
| Jun 30, 2025 | -102.81% |
| Mar 31, 2025 | -94.21% |
| Dec 31, 2024 | -77.41% |
| Sep 30, 2024 | -62.09% |
| Jun 30, 2024 | -55.16% |
| Mar 31, 2024 | -48.12% |
| Dec 31, 2023 | -43.03% |
| Sep 30, 2023 | -45.42% |
| Jun 30, 2023 | -41.85% |
| Mar 31, 2023 | -37.60% |
| Dec 31, 2022 | -42.12% |
| Sep 30, 2022 | -45.88% |
| Jun 30, 2022 | -48.66% |
| Mar 31, 2022 | -45.48% |
| Dec 31, 2021 | -79.07% |
| Sep 30, 2021 | -179.65% |
| Jun 30, 2021 | -142.02% |